, reacts with proteins and forms advanced glycation end products. In the present study, we identify a novel MG-arginine adduct and also characterize the structure of a major fluorescent adduct. In addition, we describe the immunochemical study on the MG-arginine adducts using monoclonal antibody directed to MG-modified protein. On the other hand, as an immunochemical approach to the detection of these MG adducts, we raised the monoclonal antibodies (mAb3C and mAb6B) directed to the MG-modified protein and found that they specifically recognized the major fluorescent product, argpyrimidine, as the dominant epitope. The immunohistochemical analysis of the kidneys from diabetic patients revealed the localization of argpyrimidine in intima and media of small artery walls. Furthermore, the accumulation of argpyrimidine was also observed in some arterial walls of the rat brain after middle cerebral artery occlusion followed by reperfusion. These results suggest that argpyrimidine may contribute to the progression of not only long term diabetic complications, such as nephropathy and atherosclerosis, but also the tissue injury caused by ischemia/reperfusion.
1
H NMR spectrum of this product in d6-Me 2 SO showed a singlet at 2.10 ppm corresponding to six protons; (iii) the peak corresponding to the 5-methylimidazolone derivative was not detected by the liquid chromatography-mass spectrometry with the mode of selected ion monitoring; (iv) incubation of 5-hydro-5-methylimidazolone, a putative precursor of 5-methylimidazolone, at 37°C for 14 days scarcely generated 5-methylimidazolone.
On the other hand, as an immunochemical approach to the detection of these MG adducts, we raised the monoclonal antibodies (mAb3C and mAb6B) directed to the MG-modified protein and found that they specifically recognized the major fluorescent product, argpyrimidine, as the dominant epitope. The immunohistochemical analysis of the kidneys from diabetic patients revealed the localization of argpyrimidine in intima and media of small artery walls. Furthermore, the accumulation of argpyrimidine was also observed in some arterial walls of the rat brain after middle cerebral artery occlusion followed by reperfusion. These results suggest that argpyrimidine may contribute to the progression of not only long term diabetic complications, such as nephropathy and atherosclerosis, but also the tissue injury caused by ischemia/reperfusion.
Nonenzymatic glycation (Maillard reaction) is a complex series of reactions between reducing sugars and amino groups of proteins, which leads to browning, fluorescence, and crosslinking of the proteins. The reaction is initiated with the reversible formation of a Schiff's base, which undergoes a rearrangement to form a relatively stable Amadori product. The Amadori product further undergoes a series of reactions through dicarbonyl intermediates to form advanced glycation end products (AGEs) 1 (1) . It has been shown that the formation of AGEs in vivo contributes to the pathophysiologies associated with aging and the long term complications of diabetes (2) .
A number of aldehydes and ketones, in addition to sugars, are known to form AGEs. Methylglyoxal (MG), among them, has recently received considerable attention as a mediator to form AGEs. MG is known to be formed nonenzymically by amine-catalyzed sugar fragmentation reactions (3) (4) (5) and by spontaneous decomposition of triose phosphate intermediates in glycolysis (5) . It is also a product of the metabolism of acetol, an intermediate in the catabolism of both threonine (6) and the ketone body acetone (7) . A recent study on the formation of AGEs in endothelial cells cultured under hyperglycemic conditions indicated that MG was the major precursor of AGEs (8) . Chaplen et al. (9) have shown that high levels of MG are indeed present in cultured Chinese hamster ovary cells. In addition, increased levels of MG are also found in blood from diabetic patients and in the lens of streptozotosin-induced diabetic rats (10, 11) . Che et al. (12) have reported that MG induces gene expression of heparin-binding epidermal growth factor-like growth factor by provoking oxidative stress. It is also known that MG is the physiological substrate of the glyoxalase system, which catalyzes the conversion of MG to D-lactate via the intermediate S-D-lactoylgluthathione (13) .
MG irreversibly modifies proteins under physiological conditions (14) . The reactions proceed even at physiological concentrations of MG (14) and form fluorescent products, characteristics of which resemble those occurring in proteins in aging and diabetes (15) . It has been reported that MG binds and modifies a number of proteins, including bovine serum albumin (15) (16) (17) (18) , ribonuclease A (19, 20) , lysozyme (21) , and collagen (22) . MG modification of protein may be closely associated with cellular toxicity. It has been shown that MG selectively inhibits mitochondrial respiration and glycolysis in the cells (23) . In relation to this, MG has been shown to inactivate membrane ATPases and glyceraldehyde-3-phosphate dehydrogenase, a key enzyme of the glycolytic pathway (24) . The high reactivity of MG with proteins and its relatively high concentration in the plasma (25) suggest that MG represents a common intermediate in the formation of AGEs in vivo. This assumption may be supported by the fact that macrophages have a specific receptor for proteins modified by reaction with MG, as well as for glucose-derived AGEs (18) . It has been reported that MG primarily reacts with arginine residues to form (26) . Shipanova et al. (27) have recently identified a novel MG-arginine adduct, N ␦ -(5-hydroxy-4,6-dimethylpyrimidine-2-yl)-L-ornithine (argpyrimidine), as a major fluorescent product, and the presence of this adduct in the human serum and cornea has also been demonstrated (28) . MG also reacts with lysine residues to generate an MG-derived lysinelysine cross-link (imidazolysine) (29) and N ⑀ -carboxyethyllysine (CEL) (30) , which accumulate with aging and its related diseases.
Here, we report the chemical and immunochemical characterization of the MG modification of arginine. On the basis of chemical and spectroscopic evidence, we identify a novel MG-arginine adduct having the tetrahydropyrimidine structure and also demonstrate that the major fluorescent product, originally identified as 5-methylimidazolone, is argpyrimidine. In addition, as an immunochemical approach to the detection of MG-arginine adducts in vivo, we raised the monoclonal antibodies and characterize their specificities. An attempt to detect antigenic materials in vivo was also made in the kidneys from diabetic patients and in the rat brain after ischemia/reperfusion.
EXPERIMENTAL PROCEDURES

Materials
MG (40% aqueous solution), bovine serum albumin (BSA) (essentially fatty acid-free) and N ␣ -acetyl-L-arginine were purchased from Sigma. MG was purified by distillation under reduced pressure, and the concentration of MG in stock solutions was determined by HPLC as 2-methylquinoxaline (31 
General Procedure
Separation of MG-treated N ␣ -acetylarginine was carried out on a Jasco Gulliver HPLC with a Jasco MD-910 UV-visible photodiode array detector. Low and high resolution fast atom bombardment-mass spectrometry (FAB-MS) was measured with a JEOL JMS-700 (MStation) instrument. NMR spectra were recorded with a Bruker AMX600 (600 MHz) instrument. Ultraviolet absorption spectra were measured with a Hitachi U-Best-50 spectrophotometer, and fluorescence spectra were recorded with a Hitachi F-2000 spectrometer. Liquid chromatographymass spectrometry (LC-MS) was measured with a Jasco PlatformII-LC instrument.
Reaction of N
␣ -Acetyl-L-arginine with MG N ␣ -Acetyl-L-arginine (100 mM) was incubated with MG (100 mM) in 100 mM sodium phosphate buffer, pH 7.4, at 37°C for 14 days, with adjustment of the pH to 7.4 with sodium hydroxide solution (5 M) as required. The reaction mixture was then lyophilized to dryness and extracted with ethanol. After evaporation of the ethanol under vacuum, the residual solid product was purified by reversed-phase HPLC.
HPLC Analysis
Separation was carried out in a Develosil ODS-HG-5 column (4.6 ϫ 250 mm, Nomura Chemicals Co., Seto, Japan) by applying a linear gradient of 10 -50% methanol in 50 mM acetic acid from 15 to 30 min after the isocratic condition (0.1% methanol in 50 mM acetic acid) for 15 min at a flow rate of 0.8 ml/min. The eluent was monitored at 230 nm. For preparative HPLC, the reaction mixture was applied to a Develosil ODS-HG-5 column (8.0 ϫ 250 mm), equilibrated in a solution of 15% methanol in 50 mM acetic acid, and eluted at a flow rate of 2.0 ml/min. The elution profiles were monitored by absorbance at 215 nm.
Amino Acid Analysis
BSA (1 mg/ml) in 100 mM sodium phosphate buffer (pH 7.4) was treated with 100 mM MG at 37°C for 24 h. After incubation, the reaction mixtures were treated with 10% trichloroacetic acid. Precipitated proteins were separated by centrifugation at 10,000 ϫ g for 10 min. The pellets were collected and washed with 200 l of diethyl ether. The resultant pellets were dried and subjected to acid hydrolysis with 6 N HCl at 105°C for 24 h. The hydrolysate was concentrated and dissolved with 50 mM sodium citrate buffer (pH 2.2). The amino acid analysis was performed with a JEOL JLC-500 amino acid analyzer equipped with a JEOL LC30-DK20 data analyzing system.
Monoclonal Antibodies
Female BALB/c mice were immunized three times with the MGtreated keyhole limpet hemocyanin. Spleen cells from the immunized mice were fused with P3/U1 murine myeloma cells and cultured in hypoxantine/aminopterin/thymidine selection medium. Culture supernatants of the hybridoma were screened using an enzyme-linked immunosorbent assay (ELISA), employing pairs of wells of microtiter plates on which were absorbed MG-treated BSA and native BSA as antigen (1 g of protein/well). After incubation of 50 l of hybridoma supernatants, and with intervening washes with phosphate-buffered saline, pH 7.8, containing 0.05% Tween 20 (PBS-Tween), the wells were incubated with alkaline phosphatase-conjugated goat antimouse IgG, followed by a substrate solution containing 1 mg/ml p-nitrophenyl phosphate. Hybridoma cells corresponding to supernatants that were positive on MG-modified BSA and negative on native BSA were then cloned by limiting dilution. After repeated screening, three clones were obtained. Among them, clones 3C and 6B showed the most distinctive recognition of MG-modified BSA. 
ELISA
Direct ELISA-A coating antigen was prepared by incubating 1 mg of BSA with 10 mM aldehydic compounds in 1 ml of 50 mM sodium phosphate buffer, pH 7.2, for 24 h at 37°C. A 100-l aliquot of the antigen solution containing 0.4 mg of protein was added to each well of a 96-well microtiter plate and incubated overnight at 4°C. The antigen solution was then removed, and the plate was washed with PBS-Tween. Each well was filled with 200 l of 0.5% gelatin solution for 1 h at 37°C. The primary antibody was then added to the wells at 100 l/well of 1 g/ml solution for 3 h at 37°C. The plate was then washed once with PBSTween. After discarding the supernatants and washing three times with PBS-Tween, 100 l of a 5 ϫ 10 3 dilution of goat anti-mouse IgG conjugated to horseradish peroxidase in PBS-Tween was added. After incubation for 1 h at 37°C, the supernatant was discarded, and the plates were washed three times with PBS-Tween. Enzyme-linked antibody bound to the well was revealed by adding 100 l/well 1,2-phenylenediamine (0.5 mg/ml) in 0.1 M citrate/phosphate buffer (pH 5.0) containing 0.003% H 2 O 2 . The reaction was terminated by the addition of 50 l of 2 M sulfuric acid, and the absorbance at 492 nm was read on a micro-ELISA plate reader. Competitive ELISA-For characterization of the antibody, a competitor was incubated with the antibody for 20 h at 4°C to yield competitor/ antibody mixtures containing antibody at 1 g/ml and variable concentrations of the competitor. A 100-l aliquot of the competitor/antibody mixture was added to each well and incubated for 1 h at 37°C. After discarding the supernatants and washing three times with PBS-Tween, the second antibody was added, and the enzyme-linked antibody bound to the well was revealed as described previously. Results were expressed as the ratio B/Bo, where B ϭ (absorbance in the presence of the competitor Ϫ background absorbance (no antibody)) and Bo ϭ (absorbance in the absence of the competitor Ϫ background absorbance).
Animal Experiments
The details of the operative method have been previously reported (32) . Animal experiments were carried out according to a protocol approved by the Animal Care Committee of Juntendo University. Adults male Wistar rats (SPF) weighing 250 -300 g were used (Japan SLC, Shizuoka, Japan). In anesthetized rats, the right middle cerebral artery was occluded at its origin by the insertion of a thin nylon surgical thread via the external and internal carotid arteries according to the method of Longa et al. (33) with slight modifications. After 3 h of right middle cerebral artery occlusion, the thread was removed to allow reperfusion. The body (rectal) temperature was maintained at 37°C using a heating pad and lamp-heating. All rats exhibited neurogenic deficits characterized by severe left hemiparesis, more in the upper extremity, and right Horner's syndrome, and most of the rats died after 48 h due to severe brain edema. Five rats were perfused transcardially with 4% paraformaldehyde in PBS each at 6 and 24 h after reperfusion.
Immunohistochemistry
Human Kidneys-Formalin-fixed and paraffin-embedded renal tissues derived from autopsy samples of diabetic and nondiabetic patients were prepared. The immunohistochemical localization of argpyrimidine in the tissues was examined by a labeled streptavidin biotin method using Maxitags immunoenzyme universal kit (Shandon Lipshaw, Pittsburgh, PA). In brief, the tissue sections were deparaffinized with xylene and hydrated in a series of increasing water concentrations in ethanol. The slides were then placed in a chamber containing 0.3% H 2 O 2 solution in methanol for 20 min at room temperature to inhibit the endogenous peroxidase activity, followed by the blocking step for 15 min. Subsequently, the slides were incubated with a 1:100 dilution of antiargpyrimidine mouse monoclonal antibody (mAb6B) for 2 h at room temperature. To perform immunoabsorption experiments, the antibody was preincubated with and without free N-acetylargpyrimidine (final concentration, 25 M) overnight at 4°C before application to the tissue section as described above. After the reaction with primary antibody, the slides were washed with water and PBS and incubated with biotinylated anti-mouse IgG for 30 min at room temperature, followed by another wash. In the next step, the slides were incubated with peroxidase-conjugated streptavidin for 30 min at room temperature and then washed with water. The color reaction was carried out by incubating the slides with freshly prepared 3,3Ј-diaminobenzidine reagent. After stopping the reaction by washing the slides with water, the nuclei were counterstained with hematoxylin for 20 s.
Rat Brain after Middle Cerebral Artery Occlusion Followed by
Reperfusion-The brains were removed and then postfixed with 4% paraformaldehyde in PBS. The paraffin-embedded brains were cut coronary at a thickness of 5 mm, deparaffinized with xylene, and dehydrated with 100% ethanol. Immunostaining was performed by the avidin-biotin-peroxidase complex (ABC) method as previously reported (32, 34) . After blocking endogenous peroxidase activities by treatment with 3% H 2 O 2 in methanol, the sections were incubated with 10% normal goat serum in 0.01 M PBS containing 2% BSA for 10 min at room temperature to block nonspecific binding. After washing with PBS, the sections were incubated with the monoclonal antibody (mAb6B) overnight at 4°C. After being rinsed in 0.01 M PBS, the sections were incubated with biotinylated anti-mouse IgG (1:100 dilution; Vectastain ABC kit, Vector Laboratories, Burlingame, CA) for 60 min at room temperature. They were then incubated with ABC (1:100 dilution; Vectastain ABC kit, Vector Laboratories) for 1 h. After rinsing, sections were finally incubated with 0.02% 3,3-diaminobenzidine and 0.03% H 2 O 2 in distilled water for 7-10 min. To confirm the specificity of immunostaining, competition experiments were performed with the mAb6B that was preincubated for 2 h at 37°C with an excess of argpyrimidine. Control sections were treated in the same manner with omission of the primary antibodies or with nonimmune rabbit or mouse IgG as a negative control.
RESULTS
Characterization of Major Nonfluorescent and Fluorescent MG-Arginine Adducts
The selectivity of the binding of MG to arginine residues was assessed by changes in the amino acid composition of MGtreated proteins. When BSA (1 mg/ml) was incubated with 100 mM MG for 24 h at 37°C, about 78% of the arginine and 27% of lysine residues were lost, and no significant change in other amino acids was observed. The data suggested that the arginine residues of proteins represented primary targets for reaction with MG. Hence, to determine the structure of the MGarginine adduct generated in the protein, the reaction of MG with N ␣ -acetylarginine was carried out. Upon incubation of N ␣ -acetylarginine with MG for 14 days at 37°C, two nonfluorescent products (a and b) and one fluorescent product (c) were detected ( Fig. 1) . After purification, they were characterized by 1 H and 13 C NMR, FAB-MS, and LC-MS along with N ␣ -acetylarginine. Nonfluorescent Products-The LC-MS analysis of the peaks (product b) eluted at 22-24 min exhibited the same molecular weight of 361 (MϩH) (data not shown). After purification, the product was characterized by FAB-MS and 1 H and 13 C NMR. The FAB-MS on the glycerol matrix showed a molecular ion at m/z of 361 (MϩH) (Fig. 2) . High resolution FAB-MS in the positive ion mode showed a molecular weight of 361.1729 (S.E., ϩ1.6 ppm), that corresponded to the molecular formula of C 14 methine (h or hЈ). The 13 C NMR spectrum showed the presence of two quaternary carbons linked with the guanidino group (C-l and C-m) and one carboxylic acid carbon (C-n or C-nЈ). It was suggested that the product had isomers, because C-m was an asymmetric carbon. Each signal of two methyl (f and g) and methine (h) showed two peaks by the effects of a chiral center. The methyl protons (f or fЈ) was correlated with C-h (or C-hЈ), C-l (or C-lЈ) and C-n (or C-nЈ) in the 1 H-detected multiple-bond heteronuclear multiple quantum coherence spectrum (Fig. 3) . The two-dimensional spectra also showed the correlation of another methyl protons (g or gЈ) and C-m (or C-mЈ), and of methine (h or hЈ) and C-f (or C-fЈ), C-g (or C-gЈ), C-l (or C-lЈ), and C-m (or C-mЈ). Six signals of carbon (C-f, C-g, C-h, C-l, C-m, and C-n) seemed to have originated from two molecules of MG at the reaction with the guanidino group in N ␣ -acetylarginine. Based on these characteristics, it was determined that the purified product was a novel tetrahydropyrimidine-type MGarginine adduct, N ␦ -(4-carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydropyrimidine-2-yl)-L-ornithine (Fig. 3) . The product was generated in the yield of 16.0% when N ␣ -acetylarginine was incubated with MG for 14 days at 37°C. It is also notable that a similar tetrahydropyrimidine derivative was also isolated from the reaction mixture of N ␣ -benzoylarginine with MG (data not shown).
All of the peaks (product a) eluted at 13-15 min in Fig. 1A showed an absorption maximum at 220 nm and a molecular weight of 271 upon LC-MS analysis, suggesting that they were a mixture of isomers. (Fig. 1B) . It was fluorescent, with an excitation at 320 nm and an emission at 380 nm. The 1 H NMR spectrum of the product isolated as a major fluorescent product showed a singlet at 2.60 ppm (f) corresponding to three protons in D 2 O (Fig. 4A) .1 (C-h, COOH). These data seemed to be consistent with those of the 5-methylimidazolone derivative previously reported (14) . However, several lines of evidence suggested that the structure had been erroneously reported. Low and high resolution FAB-MS gave a molecular ion peak at m/z 297 (MϩH) and a molecular formula of C 10 H 25 O 6 N 4 , respectively, which did not coincide with 5-methylimidazolone but with N ␣ -acetyl-N ␦ -(5-hydroxy-4,6-dimethylpyrimidine-2-yl)-L-ornithine (argpyrimidine), which has been recently reported by Shipanova et al. (27) . This was supported by the data that the 1 H NMR spectrum of this product in d6-Me 2 SO showed a singlet at 2.10 ppm (f) corresponding to six protons (Fig. 4B ). In addition, we noted that the chemical shift of 156.6 ppm (C-k) in 13 C NMR spectrum is too far upfield for the carbonyl carbon of the 5-methylimidazolone ring. The carbon signals of 138.8 and 156.6 ppm were reasonably assigned to the carbon adjacent to hydroxy and methyl groups in argpyrimidine, respectively. We attempted to detect the N ␣ -acetyl-5-methylimidazolone derivative (molecular weight, 269) by LC-MS with the mode of selected ion monitoring, but the peak corresponding to the product was not detected at all (Fig. 5) . Furthermore, because the formation of 5-methylimidazolone has been suggested to involve a spontaneous autoxidation of the intermediate 5-hydro-5-methylimidazolone (26), we attempted to detect 5-methylimidazolone upon incubation of 5-hydro-5-methylimidazolone in sodium phosphate buffer (pH 7.4) at 37°C for 14 days; however, 5-methylimidazolone was scarcely detected by LC-MS (data not shown). Finally, we prepared "5-methylimidazolone" following the method previously reported (14) , but the reaction provided one major fluorescent product that was chromatographically and spectrophotometrically identical to the product we isolated (data not shown). When these data were taken together, it was seen that the fluorescent product, putatively identified as 5-methylimidazolone, was identical to argpyrimidine (27) . Argpyrimidine was generated in a 3.95% yield from the reaction of N ␣ -acetylarginine with MG for 2 weeks at 37°C.
The Monoclonal Antibodies Raised against MG-modified Protein
We demonstrated that MG reacted with the arginine derivatives and generated a number of adducts, including the 5-hydro-5-methylimidazolone-type and tetrahydropyrimidine-type nonfluorescent adducts and the argpyrimidine-type fluorescent adduct. To specifically detect these MG-arginine adducts generated in vivo, we raised monoclonal antibodies directed to the MG-modified protein. During preparation of the monoclonal antibody, hybridomas were selected by comparing the reactivities of the culture supernatant to MG-modified BSA. Among three clones obtained, clones 3C and 6B showed the most distinctive recognition of MG-modified BSA. The immunoreactivity of mAb3C and mAb6B to the protein treated with aldehydes or ketones was examined by ELISA. As shown in Fig. 6 , among the compounds tested, both monoclonal antibodies recognized not only the MG-modified proteins but also the proteins treated with the trioses, including hydroxyacetone, dihydroxyacetone, glycolaldehyde, and glyceraldehyde. The result also revealed that the peroxidation products of polyunsaturated fatty acids are not the source of antigens. In addition, binding of the MG-modified protein to both antibodies was scarcely inhibited by the MG-lysine adducts (imidazolysine and CEL) and the MG-arginine adducts (5-hydro-5-methylimidazolone and tetrahydropyrimidine-type adduct) but significantly inhibited by argpyrimidine (Fig. 7) , indicating that a dominant epitope of both monoclonal antibodies is argpyrimidine. When BSA (1 mg/ml) was incubated with MG for 24 h at 37°C, there was a progressive increase in the number of argpyrimidine (from 0 to 0.118 mol/mol of protein) formed as the concentration of MG in the reaction mixture was varied from 0 to 100 mM. This result was accompanied by a progressive increase in the immunoreactivity of the protein with mAb6B. Antibody reactivity appeared proportional to the yield of argpyrimidine (Fig. 8) .
Immunohistochemical Detection of Argpyrimidine in Renal Tissues from Diabetic Patients
It has been demonstrated that the rate of MG production increases during hyperglycemia (36) . Hence, the formation of argpyrimidine in vivo was evaluated in the kidneys from diabetic patients by immunohistochemistry using anti-argpyrimidine monoclonal antibody (mAb6B). We found significant argpyrimidine immunoreactivity in intima and media of small artery walls of a diabetic kidney (57-year-old male) (Fig. 9B) , whereas vascular walls of nondiabetic kidneys were scarcely immunostained with the monoclonal antibody (75-year-old male) (Fig. 9A) . Preadsorption of mAb6B by free N ␣ -acetylargpyrimidine abolished the immunostaining (data not shown), indicating the specific reactivity of the antibody with epitopes. It is of interest to note that the staining patterns of argpyrimidine were almost identical with those of the AGEs (data not shown). Therefore, long term exposure of tissue proteins with MG in diabetic patients leads to increased tissue levels of argpyrimidine, accounting for argpyrimidine deposition in their aortic tissues.
Postischemic Accumulation of Argpyrimidine in the Rat Brain
Vascular endothelial injury, which occurs in association with ischemia/reperfusion, inflammation, xenobiotic metabolism, and other circumstances, is believed to play an important role in the initiation and progression of various vascular diseases. We tested whether antigenic materials stained with the anti- Renal tissue specimen from nondiabetic (A) and diabetic (B) patients was immunostained for argpyrimidine. In B, positivity was found in the intima and media of artery wall in a patchy distribution with red-brownish color (arrowheads).
argpyrimidine monoclonal antibody (mAb6B) are formed in the rat brain after middle cerebral artery occlusion followed by reperfusion. Histological changes in the rat brain 3 h after middle cerebral artery occlusion followed by reperfusion have been previously reported (37) . In brief, after 1 h of reperfusion, some striatal neurons become shrunken when compared with intact neurons, whereas the frontoparietal cortical neurons supplied by the middle cerebral artery do not show any pathological changes. The number of shrunken or triangular neurons increases in the lateral striatam after 3 h of reperfusion, and these atrophic neurons were further increased after 6 h. The infarcted zone spread more widely and is well demarcated. The neurons in the infarcted zone become blurred at 24 h after reperfusion.
Immunoreactivity with mAb6B was not detected in normal rat brain (data not shown), and it was also not detected at 6 h after reperfusion (Fig. 10A) . The accumulation of antigenic materials was observed in some arterial walls within the infarcted zone at 24 h after reperfusion (Figs. 10B and 11) . No immunoreactivity was identified in neuritic plaques, in glial cytoplasm, or nuclei from any cell type. It was observed that co-incubation with authentic argpyrimidine blocked the immunoreactivity of mAb6B with arteriolar walls and that nonimmune mouse IgG gave no immunostaining pattern (data not shown). The noninfarcted zone in the same section did not show any significant immunostaining (Fig. 10C) . It has been suggested that reperfusion injury after ischemia is linked to the generation of oxygen free radicals that have the capacity to initiate the destruction of biological membranes and cellular structures by activating lipid peroxidation and altering membrane phospholipids. However, the staining patterns of argpyrimidine in the brains were inconsistent with those of lipid peroxidation-specific epitopes that primarily localized in neurons, glia cells, and neuropils (36) , suggesting that the source of MG in this experimental model of ischemia/reperfusion is independent of lipid peroxidation.
DISCUSSION
The Nonfluorescent MG-Arginine Adducts-In the present study, we identified a novel MG-arginine adduct having a tetrahydropyrimidine moiety, which is expected to be formed from the reaction of the guanidino group of arginine with two MG molecules. Formation of this adduct appears to be reasonably explained by the following mechanism (Scheme I). The carbonyl carbon in the monohydrate form of MG is attacked by the guanidino group of arginine to form the Schiff's base adduct after dehydration. Another carbonyl carbon in the monohydrate form of MG is then attacked by the primary amino group of the Schiff's base intermediate, and the reaction is completed after dehydration followed by aldose condensation. Although the detailed mechanism remains unclear, it is postulated that the secondary amine derivative is an unstable intermediate that preferentially reacts with MG, leading to the formation of the tetrahydropyrimidine derivative. Alternatively, it may not be unlikely that an MG dimer having free aldehyde groups reacts with the guanidino group of arginine, generating the formation of a condensed-ring product. To assess the formation of this adduct in proteins, we attempted to analyze it in the hydrolyzed samples of protein that had been treated with MG; however, it turned out to be unfeasible because acid hydrolysis, even after sodium borohydride (NaBH4) treatment of the adduct, led to quantitative release of the arginine moiety as free arginine.
It has been proposed that the 5-hydro-5-methylimidazolone derivative consists of three tautomeric pairs of isomers that are all interconvertible by the three processes of tautomerism (35) . Such a tautomerism was also suggested from the reversedphase HPLC analysis of the reaction mixture of MG and N ␣ -acetylarginine ( Fig. 1) and from the ␦ and J values in 1 H NMR analysis of the isolated products. It has been reported that 5-hydro-5-methylimidazolone competes with MG-treated human serum albumin for binding to receptors on human monocytes, which provide a convenient monocytic model for studying receptor-mediated endocytosis of oxidized and glycated proteins (35) . A similar 5-hydro-5-methylimidazolone derivative is also formed from other ␣-oxoaldehydes, such as 3-deoxyglucosone, in biological systems (38) .
The Fluorescent MG-Arginine Adducts-Lo et al. (14) have reported that the reaction of MG with arginine residues pro- ceeds via the reversible formation of a glycosylamine and a dihydroxyimidazolidine, with slow conversion to form a fluorescent 5-methylimidazolone. Since then, 5-methylimidazolone has been suggested to represent a common structure in MGmediated advanced glycation reactions (26) . In vitro glycation of proteins in fact generates a similar imidazolone derivative, (39) . We first believed that the major fluorescent MG-arginine adduct should be 5-methylimidazolone (40) , because incubation of N ␣ -acetylarginine with MG almost exclusively generated a single fluorescent product (Fig. 1) (Fig. 4A ) agreed completely with those reported previously (14) ; in particular, the singlet at 2.60 ppm, corresponding to three protons of 5-methyl group, was decisive. However, it was doubtful that the aminoimidazolonyl structure of 5-methylimidazolone was fluorescent. This led us to reexamine the structure of the adduct. Various lines of evidence consequently proved that the fluorescent product was not 5-methylimidazolone but was identical to argpyrimidine. A number of points that contradict the 5-methylimidazolone structure are summarized as follows: the low and high resolution FAB-MS gave a molecular ion peak at m/z of 297 (MϩH) and a molecular formula of C 10 H 25 O 6 N 4 , respectively, which coincided with argpyrimidine.
The
1 H NMR spectrum of this product in d6-Me 2 SO showed a singlet at 2.10 ppm corresponding to six protons (Fig. 4B) . The chemical shift of 156.6 ppm in the 13 C NMR spectrum is too upfield for the carbonyl carbon of the 5-methylimidazolone ring, whereas the carbon signals of 138.8 and 156.6 ppm could be reasonably assigned to the carbon adjacent to hydroxy and methyl groups in argpyrimidine, respectively. The peak corresponding to the 5-methylimidazolone derivative (molecular weight, 269) was not detected by LC-MS with the mode of selected ion monitoring (Fig. 5) . In addition to this definitive evidence, we have also observed that the incubation of 5-hydro-5-methylimidazolone, a putative precursor of 5-methylimidazolone, does not generate 5-methylimidazolone.
Immunochemical Detection of Argpyrimidine-In this study, we obtained new murine monoclonal antibodies, mAb3C and mAb6B, that clearly distinguished the MG-modified protein from the native protein. It appears that both monoclonal antibodies are specific to argpyrimidine. The observation (Fig. 6 ) that the anti-argpyrimidine monoclonal IgG cross-reacted with proteins that had been treated with trioses, such as hydroxyacetone, dihydroxyacetone, and glyceraldehyde, suggested that these compounds produced similar derivatives in the protein to those generated in the MG-modified protein. In fact, proteins modified with dihydroxyacetone produce a derivative with identical fluorescence characteristics to MG-modified proteins (15) . Alternatively, they may produce MG during incubations, leading to the formation of MG-modified proteins. This may be supported by the previous observations that triose phosphates, such as glyceraldehyde-3-phosphate and dihydroxyacetonephosphate, degrade to MG (5, 41) .
The immunohistochemical analysis of the kidneys from diabetic patients revealed the formation of argpyrimidine in the arterial walls of a diabetic kidney (Fig. 9) , leading to the assumption that the formation of argpyrimidine is associated with the development of atherosclerosis in diabetic complications. Westwood et al. (18) have reported that both MG-modified proteins and glucose-derived AGEs bind to a common receptor in macrophages. Recently, one of the major epitopes of the anti-AGE antibody has been identified as N ⑀ -(carboxymethyl)-lysine, which is formed upon the reaction of lysine residues with glyoxal generated during the glycation reaction. In addition, N ⑀ -(carboxymethyl)lysine has also been reported as a product of lipid peroxidation (42): a mechanism has been proposed in which the metal-catalyzed oxidation of polyunsaturated fatty acids in the presence of protein leads to the formation of glyoxal, an intermediate formed during lipid peroxidations, reacting with lysine residues to generate N ⑀ -(carboxymethyl)lysine. The observation that the staining patterns of argpyrimidine in these deposits were almost identical with those of the AGEs 2 also suggests that dicarbonyl intermediates, such as MG and glyoxal, may contribute to the development of atherosclerosis.
Postischemic reperfusion injury is caused by several interacting factors. The immunohistochemical analysis of the rat brain after middle cerebral artery occlusion followed by reperfusion has shown that formation of argpyrimidine occurs in ischemic regions of the brain and that it is localized to the arterial walls (Figs. 10 and 11 ). These data led to the assumption that MG and/or other trioses may play a significant role in acute arterial injury due to ischemia/reperfusion. These short chain sugars generated during reperfusion may react with matrix tissue or cell surface proteins and result in the alteration of the structure and function of matrix proteins or in the stimulation of cellular responses due to the cross-linking of cell surface proteins. Our preliminary studies have also revealed the formation of argpyrimidine in some arterial walls of human brains. 3 It is therefore likely that trioses, such as MG, play an important role in vascular endothelial injury and contribute to the progression of vascular diseases, whereas neurons that are generally considered to be vulnerable to ischemic injury, such as striatal neurons, were negative for argpyrimidine during the reperfusion period. Even as the infarcted zone enlarged with prolongation of the reperfusion period, very few cortical neurons in the ischemic areas were positively stained.
In addition to arginine, lysine residues of proteins are potential targets of dicarbonyl compounds. It has been shown that MG forms a numbers of adducts with lysine residues. Brinkman et al. (43) have described an imidazolium cross-link structure, imidazolysine. This product was also detected in proteins reacted with MG in vitro and in plasma proteins (29) . In addition, Ahmed et al. (44) have recently reported a new MG-lysine adduct, CEL, that has also been shown to accumulate with aging and its related diseases. Although we were unable to raise the monoclonal antibody against these MG-lysine adducts, we have recently raised the rabbit polyclonal antiserum consisting of at least one subpopulation that reacts with imidazolysine. 4 This specific antiserum may enable us to detect the MG-lysine adduct in vivo.
In summary, we identified a novel MG-arginine adduct (tetrahydropyrimidine) and also proved that the major fluorescent product, which had been putatively identified as 5-methylimidazolone, was argpyrimidine. In addition, we raised monoclonal antibodies specific for the fluorescent adduct (argpyrimidine). Using the anti-argpyrimidine monoclonal antibody (mAb6B), the accumulation of antigenic materials in human atherosclerotic lesions and in the rat brain after middle cerebral artery occlusion followed by reperfusion was demonstrated. Because MG is known to be involved in widespread biological processes, the MG modification of arginine may contribute to the pathophysiologies associated with aging and its related diseases.
